Teva Pharmaceutical Industries Limited (TEVA)
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic
$31.69
+1.34%
Mkt Cap $36.69B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Jan 28, 2026 | $4.32B | $4.71B | +9.13% | $0.65 | $0.96 | +47.69% | — | — |
| Q4 2025 Nov 5, 2025 | $4.45B | $4.48B | +0.57% | $0.68 | $0.78 | +14.71% | — | — |
| Q3 2025 Jul 30, 2025 | $4.36B | $4.18B | -4.25% | $0.63 | $0.66 | +4.76% | — | — |
| Q2 2025 May 7, 2025 | $4.38B | $3.89B | -11.19% | $0.47 | $0.52 | +10.64% | — | — |
| Q1 2025 Jan 29, 2025 | $4.10B | $4.23B | +3.03% | $0.69 | $0.71 | +2.90% | — | — |
| Q4 2024 Nov 6, 2024 | $4.12B | $4.33B | +5.16% | $0.65 | $0.69 | +6.15% | — | — |
| Q3 2024 Jul 31, 2024 | $4.10B | $4.16B | +1.61% | $0.57 | $0.61 | +7.02% | — | — |
| Q2 2024 May 8, 2024 | $3.73B | $3.83B | +2.69% | $0.51 | $0.48 | -5.88% | — | — |
| Q1 2024 Jan 31, 2024 | $4.03B | $4.46B | +10.69% | $0.75 | $1.00 | +33.33% | — | — |
| Q4 2023 Nov 8, 2023 | $3.73B | $3.85B | +3.14% | $0.60 | $0.60 | +0.00% | — | — |
| Q3 2023 Aug 2, 2023 | $3.71B | $3.88B | +4.41% | $0.54 | $0.56 | +3.70% | — | — |
| Q2 2023 May 10, 2023 | $3.62B | $3.66B | +1.15% | $0.57 | $0.40 | -29.82% | — | — |
| Q1 2023 Feb 8, 2023 | $3.89B | $3.88B | -0.10% | $0.68 | $0.71 | +4.41% | — | — |
| Q4 2022 Nov 3, 2022 | $3.84B | $3.60B | -6.38% | $0.61 | $0.59 | -3.28% | — | — |
| Q3 2022 Jul 26, 2022 | $3.78B | $3.79B | +0.26% | $0.57 | $0.68 | +19.30% | — | — |
| Q2 2022 May 3, 2022 | $3.74B | $3.66B | -2.05% | $0.55 | $0.55 | +0.00% | — | — |
| Q1 2022 Feb 9, 2022 | $4.28B | $4.10B | -4.23% | $0.74 | $0.77 | +4.05% | — | — |
| Q4 2021 Oct 27, 2021 | $4.03B | $3.89B | -3.58% | $0.65 | $0.59 | -9.23% | — | — |
| Q3 2021 Jul 28, 2021 | $4.03B | $3.91B | -3.01% | $0.57 | $0.59 | +3.51% | — | — |
| Q2 2021 Apr 28, 2021 | $3.71B | $3.98B | +7.27% | $0.58 | $0.63 | +8.62% | — | — |